Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501167 | 0.95 | KDM4E (0.40) | KDM4ESMN1; SMN2POLB | |
| SCHEMBL21501800 | 0.89 | POLB (0.37) | KDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25488050 | 0.85 | LMNA (0.36) | KDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL20630571 | 0.84 | ALDH1A1 (0.37) | SMN1; SMN2POLBALDH1A1HSD17B10 | |
| SCHEMBL22064868 | 0.81 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL3909195 | 0.80 | ALDH1A1 (0.43) | KDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL22065258 | 0.77 | KDM4E (0.41) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL20713853 | 0.73 | ALDH1A1 (0.38) | SMN1; SMN2POLBALDH1A1HSD17B10 | |
| SCHEMBL10191818 | 0.70 | POLB (0.35) | SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL20653786 | 0.69 | KDM4E (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377065-B1 | SPIROCYCLIC PYRIDOTRIAZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3389380-B1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | SCRIPPS RESEARCH INST (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2019010165-A1 | BENZAMIDE INHIBITORS OF BACTERICAL LIPOPROTEIN SIGNAL PEPTIDASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | LPL, LIPE, LYPLA2 | KDM4E 3875/4885SMN1; SMN2 4286/4885POLB 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.